The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InIn a move reflecting strategic expansion within the growing healthcare technology sector, Medtronic announced the completion of its acquisition of SPR Therapeutics. This transaction integrates percutaneous peripheral nerve stimulation (PNS) technologies into the company's leading pain therapy portfolio. Through this acquisition, Medtronic aims to offer innovative, non-opioid treatment options for patients suffering from both chronic and acute pain.
This move comes as major medical device players, such as Abbott and Boston Scientific, seek to strengthen their shares in the multi-billion dollar pain management market. According to market data, the SPRINT technology developed by SPR Therapeutics is a qualitative addition for Medtronic to compete with traditional stimulation systems, as the company focuses on minimally invasive solutions that do not require permanent implants, a trend widely accepted in medical circles (per industry reports).
Regarding financial performance, MDT stock closed at $80.47 (close July 15, 2026), with daily trading ranging between $79.46 and $81.88. Investors are currently monitoring how the integration of this technology will impact margins in the neuroscience segment, especially as markets digest influential macroeconomic data, such as the Fed Monetary Policy Report released on July 10, 2026, which could affect financing costs for future acquisitions.
Update: Reports indicate the acquisition was valued at approximately $650 million. Financially, Medtronic expects the deal to be minimally dilutive to adjusted EPS in fiscal year 2027, turning neutral to accretive thereafter.
Update: Subsequent reports revealed that the total value of the acquisition reached $650 million. This figure highlights the scale of investment Medtronic is committing to strengthen its position in the neurostimulation market, reflecting confidence in the future returns of the SPRINT technology.